Results 121 to 130 of about 29,283 (270)

INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol

BJU International, EarlyView.
Background High‐risk non‐muscle‐invasive bladder cancer (HRNMIBC) has a variable prognosis, managed predominantly by local surgical resection and intravesical Bacillus Calmette–Guérin (BCG), or radical cystectomy (RC). Current treatments are poorly tolerated, have supply limitations and often fail to control the disease.
Ruby Lister‐Whelan, Ethan Senior, Jessica Kendall, Jamie B. Oughton, Fiona Collinson, Jon Griffin, Rachel Hubbard, Steven Kennish, Aidan Noon, Derek J. Rosario, Irbaz B. Riaz, Julie Telliez, James W. F. Catto, Syed A. Hussain   +13 more
wiley   +1 more source

Response evaluation of neoadjuvant therapy in MIBC: clinical trial‐derived evidence to guide practice

BJU International, EarlyView.
Objectives To review how response to neoadjuvant therapy (NAT) is assessed in clinical trials of muscle‐invasive bladder cancer (MIBC), and to determine whether trial‐derived evidence can inform response evaluation in contemporary practice. Subjects/Patients and Methods We searched PubMed, Embase and ClinicalTrials.gov through August 2025 for ...
Roberto Contieri, Bas W.G. van Rhijn, Richard Cathomas, Anja Lorch, Daniela Oprea‐Lager, Paramananthan Mariappan, Francesco Sanguedolce, Antoine G. van der Heijden, Laura S. Mertens, In collaboration with the EAU Imaging Section   +9 more
wiley   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Appropriate Duration of First-line Immunotherapy for 
Advanced NSCLC and Predictive Factors

Chinese Journal of Lung Cancer
First-line immunotherapy for advanced non-small cell lung cancer (NSCLC) shows significant survival benefits in patients without driver mutations, but the optimal duration of treatment remains controversial. Some studies support limiting immunotherapy to
Yue YIN, Xiaotong GUO, Jing AI, Jibo YUE, Lili DENG   +4 more
doaj   +1 more source

YBX1 Promotes Malignant Progression of HNSCC via Stabilizing NSUN2‐m5C Modified ATF4 mRNA

Cancer Science, EarlyView.
The diagram depicts the core axis and the key finding: “Targeting YBX1/NSUN2 abrogates HNSCC progression”. Within left‐sided HNSCC cells, NSUN2 mediates m5C methylation on the CDS of ATF4 mRNA; YBX1 then specifically recognizes and binds this modified site, augmenting ATF4 mRNA stability, which ultimately promotes cancer cell proliferation, migration ...
Yanwei Li, Shuang Li, Yang Li, Zhanyu Pan   +3 more
wiley   +1 more source

Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis

, 2017
The recent expanding technical possibilities to detect tumor derived mutations in blood, so-called circulating tumor DNA (ctDNA), has rapidly increased the interest in liquid biopsies. This review and meta-analysis explores the clinical value of ctDNA in
Krausz, S., Reinten, R. J., M. Strijker, F. Dijk, Besselink, M. G., van der Wel, M. J., H.W.M. van Laarhoven, C.J.M. van Noesel, Verheij, J., Soer, E. C., M.G. Besselink, van Laarhoven, H. W.M., A. Creemers, M.F. Bijlsma, Dijk, F., van Oijen, M. G.H., Bijlsma, M. F., van Oijen, M. G. H., M.J. van de Vijver, Meijer, S. L., van Noesel, C. J.M., M.J. van der Wel, Wilmink, J. W., S.L. Meijer, J.W. Wilmink, E.C. Soer, van de Vijver, M. J., van Laarhoven, H. W. M., M.G.H. van Oijen, Strijker, M., J. Verheij, S. Krausz, R.J. Reinten, van Noesel, C. J. M., Creemers, A.   +34 more
core   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

ADN tumoral circulante en pacientes con cáncer: perspectivas desde el laboratorio clínico

Advances in Laboratory Medicine
El análisis de ADN tumoral circulante (ctDNA) es un método no invasivo de gran relevancia para la caracterización molecular de los tumores sólidos, que aporta información valiosa sobre el perfil genético del cáncer. Actualmente, el análisis de mutaciones
Illana Francisco J., Fernández-Galán Esther, Muñoz-Bravo José Luis, Amado Laura Valiña, García Martín Carme, González-Fernández Carolina, Miró-Cañís Sílvia, Trapé Jaume, Martínez-Peinado Antonio, Filella Xavier, González Alvaro, Barco Sánchez Antonio, Díaz-Lagares Angel,   +13 more
doaj   +1 more source

Clinical specificity for each Target Selector ctDNA assay.

, 2019
Clinical specificity of each Target Selector ctDNA assay was validated on DNA extracted from 4ml of healthy donor plasma samples. For each of Target Selector ctDNA assay, no mutation was detected from 20 healthy donors, suggesting >99% clinical ...
Timothy T. Lu (7461308), Anh Pham (2630491), Jeffrey Chen (1569064), Manisha Patel (114605), Tony Daher (7461317), Cecile Rose T. Vibat (7461311), Jason C. Poole (7461302), Errin Samuelsz (7461314), Veena M. Singh (7461320), Shan-Fu Wu (7461305), Lyle J. Arnold (7461323)   +10 more
core   +1 more source

Elucidating PI3K/AKT/PTEN Pathway Alterations at Single‐Cell Level in CTCs From HR+/HER2− Metastatic Breast Cancer

Cancer Science, EarlyView.
Single CTC analysis revealed extensive inter‐ and intra‐patient heterogeneity of PI3K/AKT/PTEN pathway alterations in HR+/HER2− metastatic breast cancer, capturing both SNVs and CNAs, including PTEN loss‐of‐function events. Longitudinal CTC profiling also uncovered dynamic clonal evolution, highlighting its potential to complement tissue and ctDNA ...
Tania Rossi, Michela Palleschi, Caterina Gianni, Filippo Merloni, Alessandra Virga, Sara Bandini, Davide Angeli, Michela Tebaldi, Roberta Maltoni, Paola Ulivi, Antonino Musolino   +10 more
wiley   +1 more source